Purpose

To evaluate the efficacy of topical ivermectin-metronidazole combined therapy in the management of Demodex-associatedblepharitis.

Methods

Sixty patients with a diagnosis of Demodex-associatedblepharitis were recruited in a randomized clinical trial. Thirty receiving topical ivermectin (0.1%)-metronidazole (1%) gel treatment on days 0, 15 and 30. Thirty additional patients were used as a control group receiving vehicle on days 0, 15 and 30. The primary efficacy measure was the number of Demodex spp. mitesin the eyelashes of patients. The secondary outcomes included clinical improvement of signs and adverse events.

Results

Complete eradication of Demodex spp. was found in 96.6% of patients in the treatment group. Furthermore, a significant reduction of inflammation signs were found in all treated patients versus controls. None of the patients experienced any adverse effects associated with the treatment.

Conclusion

Demodex infection was controlled satisfactorily with the ivermectin (0.1%)-metronidazole (1%) gel, and no adverse effects were observed. Application of this gel for the treatment of different parasitic infections of the eyelids could be feasible, and this requires further exploration.

中文翻译：

---

外用伊维菌素-甲硝唑凝胶治疗蠕形螨引起的睑缘炎：一项随机临床试验

目的

评价外用伊维菌素-甲硝唑联合治疗蠕形螨相关性睑缘炎的疗效。

方法

在一项随机临床试验中招募了60 名诊断为蠕形螨相关性睑缘炎的患者。30 人在第 0、15 和 30 天接受外用伊维菌素 (0.1%)-甲硝唑 (1%) 凝胶治疗。另外 30 名患者用作在第 0、15 和 30 天接受载体的对照组。主要疗效指标是数量的蠕形螨属。螨虫在患者的睫毛上。次要结果包括体征和不良事件的临床改善。

结果

彻底根除蠕形螨属。在治疗组 96.6% 的患者中发现。此外，与对照组相比，在所有接受治疗的患者中发现炎症迹象显着减少。没有患者经历任何与治疗相关的不良反应。

结论

伊维菌素（0.1%）-甲硝唑（1%）凝胶对蠕形螨感染得到满意控制，未观察到不良反应。应用这种凝胶治疗眼睑的不同寄生虫感染是可行的，这需要进一步探索。